vimarsana.com

Latest Breaking News On - Groupa streptococcus strep - Page 5 : vimarsana.com

Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update

Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
American
Janet-graesser
Andrew-guggenhime
Groupa-streptococcus-strep
Groupa-strep
Financial-officervaxcyte-inc
Nasdaq
Research-development-rd-expenses
American-chemical-society-editor-choice-award
Drug-administration
Pediatric-program

"Going against the flow: a sociotechnical network analysis of endemic a" by Elizabeth Maree Carter

Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are autoimmune conditions caused by Group A Streptococcus (Group A Strep) infections. ARF/RHD are mostly eradicated from the Global North yet are endemic in many remote Aboriginal and Torres Strait Islander communities of Australia. The risk factors for ARF/RHD are similar to the material conditions of poverty, including overcrowded housing and poor access to health services. Despite extensive interventions, surveillance, and evaluation of these conditions over many years, an entrenched experience of illness persists due to a complex array of social, material, political, cultural, and economic factors. Using actor network theory (ANT) as a primary analytical lens I will examine processes leading to the current socio-technical network conformation of ongoing ARF/RHD. I focus on three nodes, each centring on a different element of this network: firstly, benzylpenicillin G (BPG) antibiotics used for prevention, secondly, echoca

Australia
Groupa-strep
Groupa-streptococcus-strep
Global-north
Torres-strait-islander

Institute for Glycomics awarded $2.66 million in NHMRC funding

Date Time Institute for Glycomics awarded $2.66 million in NHMRC funding Griffith University’s Institute for Glycomics has been awarded $2.66 million in Ideas Grant funding from the National Health and Medical Research Council (NHMRC) to aid four vital research projects. Director Professor Mark von Itzstein AO was delighted with the grant awards and said they cemented the Institute’s reputation as a leading biomedical research institute. “Our institute is focussed on translational research outcomes that diagnose, prevent and treat diseases of global impact. These grants will significantly assist our researchers to deliver on our mission to achieve a disease-free world.” Professor Michael Jennings and Dr Christopher Day were awarded $608,424.50 for the project titled ‘Structure and biophysical analysis aided design of novel toxoid vaccines for a major class of bacterial toxins’ with Dr Victor Torres, New York University.

Freda-jen
Milton-kiefel
Michael-jennings
Victor-torres
Victor-huber
Kate-seib
Mehfuz-zaman
Groupa-streptococcus-strep
Griffith-university-institute-for-glycomics
National-health
Gold-coast-health
York-university

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.